Levicept Ltd revealed Phase II clinical trial data for LEVI-04, a novel osteoarthritis treatment, at the EULAR 2026 conference. The data suggest LEVI-04 not only relieves pain but may also modify the disease by reducing bone marrow lesions linked to osteoarthritis severity. LEVI-04 showed improvements in pain and function comparable or superior to NSAIDs, with a differentiated safety profile from other treatments. Further presentations will detail its unique mechanism and clinical benefits, supporting its potential as a first-in-class therapy for osteoarthritis.
CEA Industries and YZi Labs have reached a cooperation agreement to strengthen governance at CEA Industries, which manages the world's largest corporate treasury of BNB. The agreement includes appointing three new board members with digital asset exp...
uniQure Inc. has priced an upsized public offering of 4,945,055 ordinary shares at $45.50 each, aiming to raise approximately $225 million before expenses. The funds will support the company's development of transformative gene therapies for severe d...
The TBG Dividend Focus ETF maintains a 'hold' rating due to its competitive fundamentals within its category. It offers a robust 12.75% projected EPS growth for next year and an estimated dividend yield of 3.59%, which surpasses its trailing yield of...
Bitcoin has been trading below $70,000 for about three weeks, with recent whale purchases totaling over $43 million failing to push the price above $65,000. Large investors, or whales, have dominated market activity since early June, but their buying...
HYLQ Strategy Corp. sold 54,461 HYPE tokens, generating $3.36 million at an average price of $61.76 each, realizing a 62% gain over its acquisition cost. This sale completes the monetization of its HYPE treasury position, totaling approximately 104,4...
